(Q44428905)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Cost effectiveness of screening immigrants for hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

7 February 2020

main subject

immigrant

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

William W L Wong

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Gloria Woo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

E Jenny Heathcote

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

14 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

1179-1190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Survival and prognostic indicators in compensated and decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

The Cost Effectiveness of Hepatitis Immunization for US College Students

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Natural history and prognostic factors for chronic hepatitis type B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

The natural history of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02559.X

10.1111/J.1478-3231.2011.02559.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745300%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference